Search results
Patients with ANCA-associated vasculitis who have undergone plasma exchange adjunctive therapy or usual care, maintenance therapy: cyclosporine versus maintenance therapy: cyclophosphamide Table S28.
The antineutrophil cytoplasmic antibody (ANCA)–associated vasculitides (AAV) comprise granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granu-lomatosis with polyangiitis (EGPA). These diseases affect small- and medium-sized vessels and are characterized by multisystem organ involvement.
Jun 9, 2023 · Overview of and approach to the vasculitides in adults; Patient education: Vasculitis (The Basics) Primary angiitis of the central nervous system in adults; Society guideline links: Vasculitis; Treatment and prognosis of polyarteritis nodosa; Treatment of Behçet syndrome; Treatment of Takayasu arteritis; Treatment of giant cell arteritis
Apr 8, 2021 · Treatment Principles. Treatment of severe GPA and MPA includes induction of remission, followed by maintenance of remission to prevent disease relapse. The cornerstone induction and maintenance trials presented in this review are summarized in Tables. 1 and 2, respectively.
- Karla N. Samman, Carolyn Ross, Christian Pagnoux, Jean-Paul Makhzoum
- 10.1155/2021/5534851
- 2021
- Int J Rheumatol. 2021; 2021: 5534851.
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis comprises three syndromes, all with frequent respiratory manifestations. Studies indicate that ANCA specificity is more important for prognosis, relapse risk, response to therapy and outcomes than the specific diagnosis.
Treatment options include glucocorticoids, nonglucocorticoid immunosup-pressive agents, and surgical management of vascular abnormal-ities (12).
People also ask
What is the treatment for ANCA-associated vasculitis?
What is avacopan used for in the treatment of ANCA-associated vasculitis?
Is cyclophosphamide versus azathioprine a remission maintenance therapy for ANCA?
Can ANCA titers indicate a patient's remission after cyclophosp treatment?
Apr 11, 2014 · ANCA should be detected using IIF with ELISA to confirm PR3 or MPO specificity (C) and checked at diagnosis, relapse, change of therapy, every 6 months while on treatment and annually while off treatment (B). Results should be available within 1 working day (D). Treatment should not be escalated solely on the basis of an increase in ANCA (B).
